Guggenheim raised the price target for the Travere Therapeutics Inc. (NASDAQ:TVTX) stock to “a Buy”. The rating was released on March 01, 2023, according to finviz. The research report from Stifel has initiated the stock to Hold, with a price target set at $22. The stock was initiated by Wells Fargo, who disclosed in a research note on December 05, 2022, to Overweight and set the price objective to $28. In their research brief published September 21, 2022, Bryan Garnier analysts initiated the Travere Therapeutics Inc. stock to Sell with a price target of $17.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Travere Therapeutics Inc. (NASDAQ:TVTX) raised 0.56% to close Thursday’s market session at $21.39, higher as compared to yesterday’s close. The stock price fluctuated between $20.65 and $21.72 throughout the trading session with the volume trading being 1025237 shares, which represented a significant variation when compared to the three months average volume of 1.41 million shares. The firm’s stock price fluctuated 1.09% within the last five trades and 4.90% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -20.42% in the last 6 months and 13.00% was added to its value over the previous 3 months. TVTX stock is trading at a margin of 0.19%, 0.66% and -6.99% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
As of the close of trading, TVTX deals in the Healthcare domain. The stock is trading -29.52 percent below its 52-week high and 20.03 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -20.2. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Travere Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $1.61 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 7.60 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 31.93, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.20 percent of Travere Therapeutics Inc. shares are owned by insiders, and 99.96 percent are held by financial institutions. Calvin Sandra, the SVP, Chief Accounting Officer at Travere Therapeutics Inc. (TVTX) has sold 360 shares of firm on Feb 02 at a price of $22.42 against the total amount of $8071.0. In another inside trade, Dube Eric M, Chief Executive Officer of Travere Therapeutics Inc. (NASDAQ:TVTX) sold 8,196 shares of the firm on Feb 01 for a total worth of $0.18 million at a price of $22.25. An inside trade which took place on Feb 01, SVP, GC & Corporate Secretary of Travere Therapeutics Inc. REED ELIZABETH E sold 2,590 shares of firm against total price of $57628.0 at the cost of $22.25 per share.